LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
Net Income	-2.61	-0.32	-0.08
Change in Accounts Receivable	0.01	0.01	-0.03
Change in Accounts Payable	-0	0.12	0.11
Operating Cash Flow	-1.64	-0.19	0
Total Debt Issued	0.02	0.05	0.58
Total Debt Repaid	-0.19	-0.19	-
Net Debt Issued (Repaid)	-0.17	-0.15	0.58
Issuance of Common Stock	1.05	0.28	0
Repurchase of Common Stock	-0	-0	-
Other Financing Activities	-0.01	-0.01	-
Financing Cash Flow	0.87	0.13	0.58
Net Cash Flow	0.54	-0.06	0.59
Levered Free Cash Flow	-	-0.02	-
Unlevered Free Cash Flow	-	-0.02	-
Change in Working Capital	-0.04	0.13	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.